Manual vs AI-Assisted Prescreening for Trial Eligibility Using Large Language Models-A Randomized Clinical Trial.

References:

• Deloitte . Unleash AI’s potential: measuring the return from pharmaceutical innovation. Accessed November 25, 2024. https://www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/measuring-return-from-pharmaceutical-innovation.html
• Moore TJ, Heyward J, Anderson G, Alexander GC. Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015-2017: a cross-sectional study. BMJ Open. 2020;10(6):e038863. doi:10.1136/bmjopen-2020-038863
• Davidson MH, Hsieh A, Dicklin MR, Maki KC. The imperative to enhance cost-effectiveness for cardiovascular therapeutic development. JACC Basic Transl Sci. 2024;9(8):1029-1040. doi:10.1016/j.jacbts.2023.12.005
• Deloitte . Intelligent clinical trials. Accessed November 25, 2024. https://www2.deloitte.com/content/dam/insights/us/articles/22934_intelligent-clinical-trials/DI_Intelligent-clinical-trials.pdf
• Unlu O, Shin J, Mailly CJ, et al. . Retrieval-augmented generation–enabled GPT-4 for clinical trial screening. NEJM AI. Published online June 17, 2024. doi:10.1056/AIoa2400181